Molecular Targets Phase III CoBRE

描述（由申请人提供）：路易斯维尔大学的生物医学研究卓越分子靶点中心（MT COBRE）和詹姆斯·格雷厄姆·布朗癌症中心在其I期和II期资助期间成功支持了14名初级教师的早期职业生涯。目前的申请反映了分子靶点计划及其教师的成熟。分子靶标COBRE III期应用的总体目标是确保MT COBRE教师鉴定的新靶标和化合物转化为关键的人体临床试验。几个优势增强了该计划的成功，包括：1）计划领导的稳定性; 2）成功保留了所有14名教职员工; 3）对该计划的机构支持总额超过3000万美元;以及4）创建路易斯维尔大学拥有的公司，致力于翻译MT COBRE调查人员的重要发现。MT COBRE教师在人体中测试其新型化合物的能力将使该计划与其他机构的类似计划区分开来。为此，MT COBRE支持开发了一个独特的转化研究基础设施，使30多个新目标的表征成为可能。第三阶段的应用将密切支持四个 支持这一目标的综合核心设施：1）微阵列核心; 2）分子建模核心; 3）NMR/代谢组学核心和4）动物模型核心。此外，詹姆斯·格雷厄姆·布朗癌症中心还创建了补充研究核心，这些核心将在项目的第三阶段提供给MT项目成员，包括生物统计学核心、临床试验办公室、生物物理癌症核心、细胞分选和流式细胞术核心。MT COBRE政府将继续为14名教师的发展提供密集的支持，其中许多人在癌症中心和大学内担任领导职务。詹姆斯·格雷厄姆·布朗癌症中心和路易斯维尔大学强大的转化研究基础设施将确保这一独特计划的成功和可持续性。

DESCRIPTION (provided by applicant): The Molecular Targets Center of Biomedical Research Excellence (MT COBRE) at the University of Louisville and the James Graham Brown Cancer Center has successful supported the early career of fourteen junior faculty members during its Phase I and il funding periods. The current application reflects the maturation of the Molecular Targets Program and its faculty. The overall goal of the Phase III application of the Molecular Targets COBRE will be to ensure that the novel targets and compounds which have been identified by MT COBRE faculty are translated to pivotal human clinical trials. Several strengths have enhanced the success of this program including: 1) Stability of program leadership; 2) Successful retention of all fourteen faculty members; 3) Institutional support for the program totaling over $30M; and 4) Creation of a University of Louisville-owned company dedicated to translating important discoveries of MT COBRE investigators. The ability of MT COBRE faculty to test their novel compounds in humans will distinguish this program from similar programs at other institutions.' To this end, the MT COBRE has supported the development of a unique translational research infrastructure which has enabled the characterization of more than 30 novel targets. The Phase III application will support four closely integrated core facilities which will support this goal; 1) Microarray Core; 2) Molecular Modeling Core; 3) NMR/Metabolomic Core and 4) Animal Model Core. Additionally, the James Graham Brown Cancer Center has created complementary research cores which will be available to MT Program members during the Phase III component of the program including the Biostatistics Core, Clinical Trials Office, Biophysical Cancer Core, Cell Sorting and Flow Cytometry Core. The MT COBRE administration will continue to provide intensive support for development of the fourteen faculty members, many of whom have assumed leadership roles within the Cancer Center and University. The robust translational research infrastructure at the James Graham Brown Cancer Center and University of Louisville will ensure the success and sustainability of this unique program.